A Randomized Double-blind Placebo-Controlled Phase II Study to Evaluate the Safety Efficacy and Pharmacokinetics of ARGX-113 in Patients with Myasthenia Gravis who have Generalized Muscle Weakness
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
This study is looking at the safety of an experimental drug, the study drug, in people with myasthenia gravis and how well people tolerate it.
Description
The purpose of this study is to evaluate the safety and tolerability of ARGX-113.
Details
| Condition | Myasthenia Gravis |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX7425 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.